cyrilzakka/clinical-trials huggingface dataset:
Evaluation of Postural Control After Exercise in Athletes Using Tetra Axial Posturography (tetrax1)

Tetra-ataxiametric posturography is based on the measurement and computerized elaboration of electronic signals emitted by four footplates, one for each heel and toe, respectively. These are sensitive to vertical pressure produced by a subject standing straight but in various positions (feet parallel, in tandem, eyes closed, on pads, etc.). The method yields additional parameters not obtained by the traditional monoplate stabilometers, namely, weight-distribution patterns and correlation among six combinations of paired outputs from the two heels, two toes, heel/toe of each foot, and the two diagonals (tetra-ataxiametric synchronizations).

Most athletic injuries occur at the end of an activity, when the participant is fatigue. It is likely that significant portion of the injuries result from instability of the lower extremity joints as a consequence of fatigue of the stabilizing muscles. Muscle fatigue increase postural sway, impaired muscle control, and increase the onset delay of movement. Comparing pre-exercise with post-exercise results for each athlete, should detect significant and clinically meaningful differences with the Tetra-ataxiametric measures of stability, interaction between Fourier Spectral Power Ranges of body sway, weight distributions, and synchronizations of toe parts. The method is suitable for young subjects, and the equipment is portable and tests can be conveniently carried out in a child's familiar training setting and right before/after exercise.

The goal of the present study is to measure the balance of the athletes after different types of exercises, to measure the ability of the athletes to recover different types of exercises, and to measure the influence of increasing physical fitness on balance ability. Fifty basketball and football players between the ages of 12 and 18 years old will be examined following informed consent from the children and their legal guardian. Each participant would be measured three times during the year (pre-season, middle-season, and post-season), three times each (before-training, after aerobic warming-up, and after-training) on the Tetrax. Additionally, physical parameters (as height, and weight), anatomical parameters (as leg length), and joint range of movement, would be record.


Eligibility Criteria:
Inclusion Criteria:

* age 12-18 years
* healthy athletes

Exclusion Criteria:

* children with known disturbances in bone, muscle of nervous systems
* children using medications that may cause problems in balance or coordination
Endovascular Treatment in Ischemic Stroke Follow-up Evaluation

Study like register with biomarkers samples for patient experiencing acute ischemic stroke, to assess clinical outcomes and different factors that may affect the clinical outcomes.


Eligibility Criteria:
Inclusion Criteria:

* Age 18 and older (i.e., candidates must have had their 18th birthday)
* Neuroimaging demonstrates acute ischemic stroke with large vessel proximal with the use of neuro-thrombectomy devices intended to restore blood flow
* No upper or lower limits of the neurological severity at baseline (NIHSS).
* With or without intravenous thrombolysis
* Oral informed consent (patient and/or trustworthy person)

Non-inclusion Criteria:

* Pregnant or breast-feeding women
* Patient benefiting from a legal protection
* Non-membership of a national insurance scheme
ALHIV Smartphone Game Study

This is a cluster-randomized controlled trial that aims to conduct comprehensive feasibility testing of a smartphone game in a sample of 120 adolescents living with HIV (ALHIV) ages 15-18 in Kisumu, Kenya, to determine whether the game influences behavioral mediators of engagement in care and sexual risk avoidance and reduction (including knowledge, attitudes, behavioral intentions, and self-efficacy).

This is a cluster-randomized feasibility study that will involve clinic-level randomization of 120 ALHIV participants (12 from each of 10 clinical centers). Participants will either use the intervention (a smartphone game) or continue standard treatment and support for HIV. Participants will complete 5 surveys about behaviors, attitudes, knowledge, and self-efficacy relating to engagement in care, ART adherence, and sexual and reproductive health. They will also have blood drawn 3 times to measure their HIV viral load. Intervention-arm participants will also complete app experience surveys. A sample of intervention-arm participants will be invited to provide feedback on their experience in interviews (n=10) and/or focus groups (n=30).

Eligibility Criteria:
Adolescents, male and female, aged 15-18 in Kisumu County (n=120)

Inclusion criteria:

* Aged 15-18 at time of recruitment
* Diagnosed with HIV and aware of HIV status
* Initiated ART at least 6 months prior
* Accesses HIV-related care at intervention arm CCC
* VL above 200 copies/ml at last test, with last test conducted within 12 months prior to recruitment date

Exclusion criteria

* Does not have basic literacy in English (Grade 3-4 on the Flesch-Kincaid Reading Scale)
* Sibling to an adolescent already enrolled in study
* Sibling to adolescent that participated in formative research
* Participant in formative research to inform study
* Participant in any Tumaini game activities
* Enrolled in boarding school
* Last recorded viral load test \>12 months prior to recruitment date
The Study of Surgery,Chemotherapy and Autologous T Cells-Based Immunotherapy for Advanced Gastric Cancer.

Evaluate the feasibility ,safety and efficacy of Surgery，Chemotherapy in Combination with Autologous T cells-Based Immunotherapy for Advanced Gastric Cancer.

Safety:AE/SAE Efficacy:immunologic function;FPS

Eligibility Criteria:
Inclusion Criteria:

* Aged between 18 to 80 years, males and females.
* Subjects who understand and sign the consent form for this study.
* The pathologically confirmed advanced gastric cancer T3、T4 or T2 and Metastasis in lymph nodes.
* Subjects are surgical candidates.
* No distant metastasis (M0) and No distant lymph node metastasis.
* Expected survival time of at least 6 months.

Exclusion Criteria:

* Subjects who do not sign the consent form for this study.
* The subject has an allergic history of medicine or food.
* The subject has uncontrolled or hard-to-control diseases of cardiovascular,liver,kidney or lung,endocrine system.
* The subject tests positive for: HIV, hepatitis virus, syphilis or other infectious diseases.
* The subject has an history of other malignant tumour.
* The subject has history of alcoholism, drug abuse, or mental illness in the 12 years prior to this trial.
* The subject has participated in any other clinical trial in the 3 months prior to this trial.
* The subject is pregnant, lactating or planning to conceive within the next 24 months.
* The subject has any other unsuitable or adverse condition to be determined by the investigator.
The Features Behind the Beneficial Effects of Interval-walking

A single bout of Interval-Walking (IW) exercise is superior to energy-expenditure and time-duration matched Continuous Walking (CW) exercise upon improving glycemic control. The reason IW is superior is unknown.

This study will look into whether it is the larger peak intensity during IW or if it is the alternating exercise pattern that is responsible for the larger improvements seen.

Subjects with type 2 diabetes will be included in a crossover, counter-balanced, controlled study, where each subject will undergo three trials. Trials will be identical except the following interventions:

1. One hour of rest (Con)
2. One hour of classical interval walking (repeated cycles of 3 min of fast and 3 min of slow walking; IW3)
3. One hour of fast alternating interval walking (repeated cycles of 1 min of fast and 1 min of slow walking; IW1).

After the interventions subjects will undergo a standardized mixed meal tolerance test, with consecutive measurements of blood glucose, insulin and c-peptide.


Eligibility Criteria:
Inclusion Criteria:

* Type 2 diabetes mellitus
* Body mass index \> 18 but \< 40 m2/kg
* Agreement to pause antidiabetic medication from 2 days before to after each trial

Exclusion Criteria:

* Pregnancy
* Smoking
* Use of exogenous insulin
* Contraindication to increased levels of physical activity
* Evidence of thyroid, liver, lung, heart or kidney disease
Stronger Together Global Registry

A global, prospective, non-randomized, multicenter, observational, post-market, medical record review registry evaluating real-world evidence for SeaSpine products.

To gain observational, prospective, real-world clinical, and radiographic data in order to evaluate continued safety and performance following the implantation of SeaSpine products.

Eligibility Criteria:
Inclusion Criteria:

* Have been treated with at least one SeaSpine product.
* Have obtained radiographic imaging, as part of the standard of care, at the following time points: preoperative and postoperative.
* Have obtained at least one preoperative patient-reported outcome measure, as part of the standard of care.
* Patient is planned, per standard of care, to be assessed with radiographic imaging and consistent patient-reported outcome measure(s) from preoperative through at least two scheduled follow-up visits.

Exclusion Criteria:

* Was not implanted with at least one SeaSpine product during operation
* Any other condition that the Investigator determines is unacceptable for enrollment into this registry
Treatment of Adenovirus Disseminated Infections in Hematopoietic Stem Cell Transplant Patients With Adenovirus Digestive Replication

Disseminated Adv infections are associated with high morbidity and mortality in HSCT pediatric patients. The most common source of Adv infection after pediatric HSCT is the host digestive tract where latent Adv are reactivated after engraftment. We have shown in a monocentric study that Adv viral load in stools is a predictive factor of blood infection in children with digestive Adv infections. We assume that an early treatment, with antiviral drugs, such as cidofovir and brincidofovir, may avoid severe Adv infections and diseases and thus that molecular surveillance in stool is a critical factor for the control of Adv reactivations.

The study has two main objectives: (i) confirming the impact of Adv viral load in stools on the occurrence of blood infection based on a multicentric prospective cohort study design; and (ii) determining the prognostic and predictive factors for efficacy and toxicity of antiviral drugs, such as brincidofovir and cidofovir.


Eligibility Criteria:
Inclusion Criteria:

* Allogeneic hematopoietic stem cell transplantation from any donor other than full-matched related donor
* Age above 2 months and under 20 years
* Provide written informed consent from the parents (if \<18) and child
* Free, informed and written consent, signed by the patient and investigator before any Study examination. If the patient is a minor by child (if possible) and both parents or child and the legal representative in case only one parent is alive

Exclusion Criteria:

* Hematopoietic stem cell transplantation from full-matched related donor
* Females who are pregnant or currently nursing
* Any patient receiving cidofovir, ribavirin or any other anti-viral drug under development given in order to treat or prevent
* Current disease attributed to adenovirus infection
* Lack of affiliation to a social security scheme (as a beneficiary or assignee).Current disease attributed to adenovirus infection
A Detailed Look At What Patients Experience When They Take Part In Hypertension Clinical Trials

This research study aims to identify the obstacles faced by specific demographic groups of hypertension patients during their engagement in clinical trials. The study will collect in-depth information from participants and identify common factors that impede their enrollment or successful completion of these trials.

By examining data from various demographic perspectives, the study aims to identify patterns impacting future hypertension patients' experiences.


Eligibility Criteria:
Inclusion Criteria:

* Patient is at least 18 years of age
* Diagnosis of hypertension
* Ability to understand the study procedures, benefits and risks, and sign a written informed consent document.

Exclusion Criteria:

* Enrolled in another research study
* Inability to provide written informed consent
* Women of childbearing potential without a negative pregnancy test; or women who are lactating.
Intermediate and Long-term Efficacy of Endovascular Treatment for TASC C&D Aortoiliac Occlusive Disease

This is a prospective, multicenter, real-world, registry study, which aims to observe the intermediate and long-term efficacy of different endovascular treatments for TASC C\&D aortoiliac occlusive disease.

Currently, the optimal therapy for TASC C and D type aortic occlusive disease is still controversial. The evidence comes from several singe-center studies with small sample size. In addition, the long-term efficacy of stent implantation and drug coated device in aortic occlusive disease remains unclear, which might be affected by the type of stent and calcification extent. Thus, this study aims to observe the intermediate and long-term efficacy of different endovascular treatments for TASC C\&D aortoiliac occlusive disease in multiple centers.

Eligibility Criteria:
Inclusion Criteria:

* Rutherford classification of 3-6
* Willing to comply with all follow-up evaluations at the specified times
* Target lesion(s) located within the native infrarenal abdominal aorta and/or common iliac artery and/or external iliac artery
* Evidence of ≥ 50% stenosis, restenosis (from PTA or adjunct therapy, not including stents or stent grafts), or occlusion of target lesion(s), or arterial thrombosis underwent PMT or CDT
* Provides written informed consent

Exclusion Criteria:

* Contraindication or known untreatable allergy to antiplatelet therapy, anticoagulants, thrombolytic drugs, or any other drug used during the study
* Known hypersensitivity to contrast material that cannot be adequately pretreated
* Bleeding diathesis or coagulopathy, known hypercoagulable condition or refuses blood transfusion
* Female currently breastfeeding, pregnant, or of childbearing potential not using adequate contraceptive measures
* Life expectancy less than 24 months
* Current participation in an investigational drug or other device study
* Severe comorbid conditions
* Myocardial infarction or stroke within 3 months prior to enrollment
Shared Care for Patients With Type 2 Diabetes Across the Primary and Secondary Health Care Sector

The aim of the study is to test the effect of a new shared care model for type 2 diabetes care and compare it with a standardized care management program in a specialized hospital-based out-patient clinic.

The hypothesis is that participants with type 2 diabetes followed in a shared care program will have a comparable outcome in HbA1c to participants receiving standard care.

The prevalence of patients with type 2 diabetes is in growth globally. In order to secure high quality in diabetes care it is necessary to rethink the way in which the care is organized. The investigators want to test a new model of shared care across the interface of primary and secondary care sector for patients with type 2 diabetes who are at risk stratification level 2. Based on a national and regional risk stratification model patients can be stratified to three levels according to risk and complexity of treatment: level 1 (uncomplicated), level 2 (intermediate risk) and level 3 (high risk).

The objective of the study is to show equal outcomes among the participants being treated in either a shared care program or an established program in a specialized outpatient clinic.

The study is a non-inferiority randomized controlled trial. The shared care model will be tested during a period of three years. All participants are offered four medical visits a year. The shared care intervention consists of one annual comprehensive check-up at the outpatient clinic and three quarterly visits at a general practice. The control group is followed with four quarterly visits at the outpatient clinic including an annual comprehensive check-up. The recruitment period spans over approximately 12 months, and participants are randomized to intervention or control group in a 1:1 ratio.

Eligibility Criteria:
Inclusion Criteria:

* Must be over the age of 18 years
* The diagnosis of type 2 diabetes
* Risk stratification level 2
* Capable of speaking and writing in Danish
* Give oral and written consent before entering the study

Exclusion Criteria:

* Diagnosed with other types of diabetes than type 2 diabetes
* Risk stratification level 1 or 3
* Being pregnant or breastfeeding
* Having severe co-morbidity with life expectancy less than five years
* Being under such conditions, that the patient will not be able to show up or go through with the appointments (e.g. moderate to severe dementia and severe psychiatric conditions)
* Participating in long-lasting interventions (\>2 weeks) that potentially affects the primary outcome in our study or patients participating in studies which include blood sampling amounting to \>5 % of the blood volume two months prior to the randomisation and/or the follow-up visits
A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy

Open-label study to allow pediatric patients who have participated in prior Levetiracetam (Keppra®) studies to continue their treatment with adequate monitoring and standardized follow-up care until Levetiracetam (Keppra®) is approved for use in children or until the completion of the development program for pediatrics.


Eligibility Criteria:
Inclusion Criteria:

* Have completed Study N151, or any other applicable pediatric trials of Levetiracetam (Keppra®)
* Be a patient for whom the treatment of Levetiracetam (Keppra®) would be of potential benefit such that the patient/parent(s)/legal guardian and the Investigator agree to continue treatment.

Exclusion Criteria:

* Not be on a ketogenic diet (during the course of this study).
* Not have seizures too close together to accurately count (i.e., the patient's seizures must be countable).
Active Surveillance of Papillary Thyroid Microcarcinoma

Papillary thyroid microcarcinoma are small thyroid cancer measuring 1cm or less. Most of this tumor are not palpable and are identified either through pathologic examination or from imaging modalities, such as CT scan or thyroid sono. Active surveillance of papillary microcarcinoma is to observe thyroid papillary cancer without immediate surgical approach. The purpose of this study is to understand more about the characteristics of papillary microcarcinoma, which has been known for "the cancer slowly progression"


Eligibility Criteria:
Inclusion Criteria:

1. \< 1 cm solitary nodule
2. Surrounded by ≥ 2 mm normal thyroid parenchyma
3. Subcapsular locations not adjacent to surrounding structures, recurrent laryngeal nerve, trachea, or carotid artery
4. No evidence of invasion to surrounding structures, recurrent laryngeal nerve, trachea or carotid artery
5. No extrathyroidal extension
6. Clinically N0 and Clinically M0
7. ≥ 18 years
8. Combined severe comorbidities or Inoperable condition (optional)
9. No wish to surgery and Willingness to accept active surveillance
10. No history of radiotherapy on head and neck area
11. Accepted by the Board of Thyroid Cancer Meeting

Exclusion Criteria:

1. ≥ 1 cm nodule and multifocal nodules regardless of size
2. Papillary thyroid carcinoma variants associated with poor prognosis (tall cell variant, columnar variant, hobnail variant) or other types of thyroid cancer)
3. Subcapsular locations adjacent to surrounding structures, recurrent laryngeal nerve, trachea or carotid artery
4. Evidence of invasion to surrounding structures, recurrent laryngeal nerve, trachea or carotid artery
5. Extrathyroidal extension
6. Any of N1 or M1
7. Documented increase in size according to America Thyroid Association (ATA) guideline in a previously confirmed Papillary thyroid microcarcinoma
8. \< 18 years
9. Not willing to accept observational active surveillance approach
Community Health Worker Based Intervention to Improve Palliative Care

The study aims to find out if community health worker (CHW) support will improve palliative care outcomes in African American patients with advanced cancer, by comparing the quality of life of patients who are receiving standard care to those whose standard care is supplemented with CHW support.

This research is being done to establish the effectiveness of a Community Health Worker based palliative care intervention among African American patients with advanced solid organ malignancies and their care givers.

The investigators' long-term goal is to reduce the research-to-practice gap in utilization of evidence-based palliative care (PC) in African Americans with advanced cancer. The objectives of this study are to establish the effectiveness of a CHW-based palliative care intervention and develop generalizable knowledge on how contextual factors influence implementation.

Eligibility Criteria:
Patient Inclusion Criteria:

* Self-identified African American patients with advanced (AJCC stage III or IV) solid organ malignancy
* \>=18 years old
* English speaking
* Intact cognition and ability to provide informed consent

Patient Exclusion Criteria:

* Participants \< 18 years of age
* Participants who are already receiving palliative care services

Caregiver Inclusion Criteria:

* Adult (\>=18 years old) caregivers providing informal (unpaid) care to an eligible African American cancer patient (related or unrelated)
* English speaking
* Intact cognition and ability to provide informed consent

Caregiver Exclusion Criteria:

* Participants \< 18 years of age